肋间注射脂质体布比卡因治疗肋骨骨折:一项前瞻性随机对照试验
本研究为在一级创伤中心开展的前瞻性、双盲、随机安慰剂对照试验(美国食品药品监督管理局研究性新药研究),纳入100例18岁以上、因钝性胸壁创伤入住ICU且不能达到50%目标吸气量的患者,随机接受脂质体布比卡因或生理盐水肋间注射(最多6个肋间)。主要终点为96小时内的疼痛评分和爆发痛用药,次终点为镇痛对肺生理的影响。结果两组每日平均疼痛评分无变化,阿片使用随时间下降但组间无差异;布比卡因组第1、2天激励肺量计容积更高(1095 mL、1063 mL vs 对照组900 mL、866 mL),但住院和ICU时间、肺炎、硬膜外导管使用及不良事件均无差异。作者认为该方法安全但未有效减少疼痛评分、阿片需求或住院时间,肺量计容积改善是短暂的且未减少肺炎发生。
要点
- 纳入标准为18岁以上、钝性胸壁创伤入住ICU且不能达到50%目标吸气量的患者,随机接受脂质体布比卡因或生理盐水肋间注射(最多6个肋间)。
- 两组每日平均疼痛评分无变化,96小时内爆发痛用药无差异,阿片使用随时间下降但组间无差异。
- 布比卡因组第1天激励肺量计容积1095 mL vs 对照组900 mL,第2天1063 mL vs 866 mL,但改善是短暂的。
- 住院时间、ICU时间、注射后肺炎、硬膜外导管使用及不良事件组间均无差异。
- 作者结论:肋间脂质体布比卡因注射是安全的镇痛方法,但未有效减少疼痛评分、阿片需求或住院时间,肺量计容积改善未减少肺炎发生。
适用人群与场景
- 18岁以上、因钝性胸壁创伤入住ICU、不能达到大于50%目标吸气量的患者。
诊断标准与关键阈值
- 纳入标准:18岁以上,钝性胸壁创伤入住ICU,不能达到大于50%目标吸气量。
处置流程与药物剂量
- 患者随机接受脂质体布比卡因或生理盐水肋间注射,最多6个肋间。
- 主要终点为96小时内疼痛评分和爆发痛用药;次终点为镇痛对肺生理的影响。
研究设计与关键结果
- 研究类型:前瞻性、双盲、随机安慰剂对照试验,在一级创伤中心开展,为美国食品药品监督管理局研究性新药研究;共纳入100例患者,每组50例。
- demographics:平均年龄60.5岁,47%为女性;损伤严重度评分布比卡因组17.9 vs 对照组17.6,合并症相似;肋骨骨折数量、分布和注射目标组间相似。
- 主要终点:两组每日平均疼痛评分无变化;两组阿片使用随时间下降,但组间无差异。
- 次要终点:布比卡因组第1天激励肺量计容积1095 mL vs 对照组900 mL,第2天1063 mL vs 对照组866 mL。
- 住院时间、ICU时间、注射后肺炎、硬膜外导管使用及不良事件组间均无差异。
证据类型、等级与局限
- 证据类型:前瞻性、双盲、随机安慰剂对照试验;证据等级:治疗/护理管理,Level II。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为肋间脂质体布比卡因注射是肋骨骨折相关镇痛的安全方法,但未有效减少疼痛评分、阿片需求或住院时间;布比卡因注射短暂改善激励肺量计容积,但未减少肺炎发生。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Blunt chest wall injury accounts for 15% of trauma admissions. Previous studies have shown that the number of rib fractures predicts inpatient opioid requirements, raising concerns for pharmacologic consequences, including hypotension, delirium, and opioid dependence. We hypothesized that intercostal injection of liposomal bupivacaine would reduce analgesia needs and improve spirometry metrics in trauma patients with rib fractures.
METHODS: A prospective, double-blinded, randomized placebo-control study was conducted at a Level I trauma center as a Food and Drug Administration investigational new drug study. Enrollment criteria included patients 18 years or older admitted to the intensive care unit with blunt chest wall trauma who could not achieve greater than 50% goal inspiratory capacity. Patients were randomized to liposomal bupivacaine or saline injections in up to six intercostal spaces. Primary outcome was to examine pain scores and breakthrough pain medications for 96-hour duration. The secondary endpoint was to evaluate the effects of analgesia on pulmonary physiology.
RESULTS: One hundred patients were enrolled, 50 per cohort, with similar demographics (Injury Severity Score, 17.9 bupivacaine 17.6 control) and comorbidities. Enrolled patients had a mean age of 60.5 years, and 47% were female. Rib fracture number, distribution, and targets for injection were similar between groups. While both groups displayed a decrease in opioid use over time, there was no change in mean daily pain scores. The bupivacaine group achieved higher incentive spirometry volumes over Days 1 and 2 (1095 mL, 1063 mL bupivacaine vs. 900 mL, 866 mL control). Hospital and intensive care unit lengths of stay were similar and there were no differences in postinjection pneumonia, use of epidural catheters or adverse events bet ween groups.
CONCLUSION: While intercostal liposomal bupivacaine injection is a safe method for rib fracture-related analgesia, it was not effective in reducing pain scores, opioid requirements, or hospital length of stay. Bupivacaine injection transiently improved incentive spirometry volumes, but without a reduction in the development of pneumonia.
LEVEL OF EVIDENCE: Therapeutic/care management, Level II.
参考来源
- Wallen TE, Singer KE, Makley AT, et al. Intercostal liposomal bupivacaine injection for rib fractures: A prospective randomized controlled trial. J Trauma Acute Care Surg. 2022. PMID: 34789700. doi:10.1097/TA.0000000000003462
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。